deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03970616

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma (DEDUCTIVE)

A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Sponsor: AVEO Pharmaceuticals, Inc.

Conditions Hepatocellular Carcinoma
Interventions Durvalumab Tivozanib
Updated 15 times since 2019 Last updated: Jul 10, 2023 Started: Sep 30, 2019 Primary completion: Apr 4, 2023 Completion: Apr 4, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.

Other terminated trials from AVEO Pharmaceuticals, Inc.

More terminations from AVEO Pharmaceuticals, Inc.

Listed as NCT03970616, this PHASE1/PHASE2 trial focuses on Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by AVEO Pharmaceuticals, Inc., it has been updated 15 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jun 2019 – ~Nov 2019 · 5 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Jul 2020 · 6 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Aug 2023 · 8 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Aug 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  5. Dec 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Oct 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jun 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AVEO Pharmaceuticals, Inc.
  • AstraZeneca
Data source: AVEO Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations